Figure 6.

Correlations between TSPO expression and in-vivo binding of radioligands in human brains. A-C: Western blot analysis of TSPO expression in gray matter of frontal cortex (same individuals as determined in autoradiogram) with an original antibody, NP157, and commercially available (C.A.) antibody (A). Quantitative analysis showed excellent correlation between TSPO expression determined by these two antibodies (B), and significant increase in TSPO expression detected by either C.A. or NP157 in AD brain compared with HC (n = 5 in each group, t = −4.971, **p < 0.01, by independent t-test, for C.A., t = −4.404, **p < 0.01, by independent t-test, for NP157). D, E: The correlation between in-vitro binding of ¹¹C-PK11195 and TSPO expression detected by immunoblot with either C.A. or NP157 was not significant (D), and similar analysis demonstrated significant positive correlations between in-vitro binding of ¹⁸F-FEBMP and TSPO expression detected by immunoblot with either C.A. or NP157 (E). Data were from immunoblotting and autoradiographic analyses shown in panel A and Figure 4, respectively. Correlation between two parameters was examined by parametric test with Pearson product-moment correlation coefficient (R).